Multifaceted impact of host C-C chemokine CCL2 in the immuno-pathogenesis of HIV-1/M. tuberculosis co-infection

Frontiers in Immunology

Volumn 4, Issue OCT, 2013, Pages

  Wahid Ansari, A ^a   Kamarulzaman, Adeeba ^a   Schmidt, Reinhold E ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CCL2; CD4+ T cells; Granuloma; HIV Mtb co infection; Immuno pathogenesis; Macrophages; Viremia

Indexed keywords

CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOGENESIS; LONG TERMINAL REPEAT; MACROPHAGE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RECURRENT DISEASE; SHORT SURVEY;

EID: 84885417693     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00312     Document Type: Short Survey

References (98)

1. UNAIDS. Chapter 2: Epidemic Update. UNAIDS Report on the Global AIDS Epidemic 2010. (2010). Available from http://www.unaids.org/documents/20101123_GlobalReport_Chap2_em.pdf.
2. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis (2010) 50(Suppl 3):S201-7. doi: 10.1086/651492.
3. Ansari AW, Bhatnagar N, Dittrich-Breiholz O, Kracht M, Schmidt RE, Heiken H. Host chemokine (C-C motif) ligand-2 (CCL2) is differentially regulated in HIV type 1 (HIV-1)-infected individuals. Int Immunol (2006) 18:1443-51. doi:10.1093/intimm/dxl078.
4. Ansari AW, Heiken H, Moenkemeyer M, Schmidt RE. Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. Immunol Lett (2007) 110:1-5. doi:10.1016/j.imlet.2007.02.012.
5. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev (2002) 4:165-76.
6. Falvo JV, Ranjbar S, Jasenosky LD, Goldfeld AE. Arc of a vicious circle: pathways activated by Mycobacterium tuberculosis that target the HIV-1 long terminal repeat. Am J Respir Cell Mol Biol (2012) 45:1116-24. doi:10.1165/rcmb.2011-0186TR.
7. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis (2003) 188:1146-55. doi:10.1086/378676.
8. Toossi Z, Mayanja-Kizza H, Lawn SD, Hirsch CS, Lupo LD, Butera ST. Dynamic variation in the cellular origin of HIV type 1 during treatment of tuberculosis in dually infected subjects. AIDS Res Hum Retroviruses (2007) 23:93-100. doi:10.1089/aid.2006.0050.
9. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol (2001) 2:123-8. doi:10.1038/84219.
10. Rollins BJ. Chemokines. Blood (1997) 90:909-28.
11. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity (2000) 12:121-7. doi:10.1016/S1074-7613(00)80165-X.
12. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res (2010) 70:109-18. doi:10.1158/0008-5472.CAN-09-2326.
13. Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T, et al. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J (2004) 68:671-6. doi:10.1253/circj.68.671.
14. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 475:222-5. doi:10.1038/nature10138.
15. Rafei M, Berchiche YA, Birman E, Boivin MN, Young YK, Wu JH, et al. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J Immunol (2009) 183:1759-66. doi:10.4049/jimmunol.0900523.
16. Sorensen TL, Ransohoff RM, Strieter RM, Sellebjerg F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol (2004) 11:445-9. doi:10.1111/j.1468-1331.2004.00796.x.
17. Ansari AW, Heiken H, Meyer-Olson D, Schmidt RE. CCL2: a potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur J Immunol (2011) 41:3412-8. doi:10.1002/eji.201141676.
18. Mengozzi M, De Filippi C, Transidico P, Biswas P, Cota M, Ghezzi S, et al. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood (1999) 93:1851-7.
19. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Cell Mol Biol (1998) 19:513-21. doi:10.1165/ajrcmb.19.3.2815.
20. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr (2001) 28:1-8. doi:10.1097/00126334-200109010-00001.
21. Diedrich CR, Flynn JL. HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun (2011) 79:1407-17. doi:10.1128/IAI.01126-10.
22. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med (2003) 168:1346-52. doi:10.1164/rccm.200306-837OC.
23. Lewinsohn DA, Winata E, Swarbrick GM, Tanner KE, Cook MS, Null MD, et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog (2007) 3:1240-9. doi:10.1371/journal.ppat.0030127.
24. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829-33. doi:10.1038/382829a0.
25. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 270:1811-5. doi:10.1126/science.270.5243.1811.
26. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833-5. doi:10.1038/382833a0.
27. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 273:1856-62.
28. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 360:692-8. doi:10.1056/NEJMoa0802905.
29. Trumpfheller C, Tenner-Racz K, Racz P, Fleischer B, Frosch S. Expression of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES genes in lymph nodes from HIV+ individuals: correlation with a Th1-type cytokine response. Clin Exp Immunol (1998) 112:92-9. doi:10.1046/j.1365-2249.1998.00555.x.
30. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 11:1170-2. doi:10.1038/nm1319.
31. Ansari AW, Meyer-Olson D, Schmidt RE. Selective expansion of pro-inflammatory chemokine CCL2-loaded CD14(+)CD16(+) monocytes subset in HIV-infected therapy naive individuals. J Clin Immunol (2013) 33:302-6. doi:10.1007/s10875-012-9790-0.
32. Bernasconi S, Cinque P, Peri G, Sozzani S, Crociati A, Torri W, et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J Infect Dis (1996) 174:1098-101. doi:10.1093/infdis/174.5.1098.
33. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, Vicenzi E, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 12:1327-32. doi:10.1097/00002030-199811000-00014.
34. Fantuzzi L, Spadaro F, Vallanti G, Canini I, Ramoni C, Vicenzi E, et al. Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages. Blood (2003) 102:2334-7. doi:10.1182/blood-2002-10-3275.
35. Ansari AW, Schmidt RE, Heiken H. Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: in vivo and in vitro findings. Clin Immunol (2007) 125:1-4. doi:10.1016/j.clim.2007.07.003.
36. Card CM, Keynan Y, Lajoie J, Bell CP, Dawood M, Becker M, et al. HIV controllers are distinguished by chemokine expression profile and HIV-specific T-cell proliferative potential. J Acquir Immune Defic Syndr (2012) 59:427-37. doi:10.1097/QAI.0b013e3182454fcd.
37. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS (2011) 6:163-8. doi:10.1097/COH.0b013e328344f35e.
38. Campbell GR, Watkins JD, Singh KK, Loret EP, Spector SA. Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol (2007) 81:5919-28. doi:10.1128/JVI.01938-06.
39. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 404:407-11. doi:10.1038/35006097.
40. Jourdan P, Abbal C, Noraz N, Hori T, Uchiyama T, Vendrell JP, et al. IL-4 induces functional cell-surface expression of CXCR4 on human T cells. J Immunol (1998) 160:4153-7.
41. Orme IM. Immunity to mycobacteria. Curr Opin Immunol (1993) 5:497-502. doi:10.1016/0952-7915(93)90029-R.
42. Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev (2003) 14:467-77. doi:10.1016/S1359-6101(03)00054-6.
43. Collins HL, Kaufmann SH. The many faces of host responses to tuberculosis. Immunology (2001) 103:1-9. doi:10.1046/j.1365-2567.2001.01236.x.
44. Kang DD, Lin Y, Moreno JR, Randall TD, Khader SA. Profiling early lung immune responses in the mouse model of tuberculosis. PLoS One (2011) 6:e16161. doi:10.1371/journal.pone.0016161.
45. Kahnert A, Hopken UE, Stein M, Bandermann S, Lipp M, Kaufmann SH. Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis (2007) 195:46-54. doi:10.1086/508894.
46. Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest (2012) 123:712-26. doi:10.1172/JCI65728.
47. Kalsdorf B, Skolimowska KH, Scriba TJ, Dawson R, Dheda K, Wood K, et al. Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis. Eur J Immunol (2013) 43:540-9. doi:10.1002/eji.201242804.
48. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol (2007) 85:103-11. doi:10.1038/sj.icb.7100027.
49. Kipnis A, Basaraba RJ, Orme IM, Cooper AM. Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis. Immunology (2003) 109:547-51. doi:10.1046/j.1365-2567.2003.01680.x.
50. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun (2002) 70:1684-93. doi:10.1128/IAI.70.4.1684-1693.2002.
51. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol (2004) 25:75-84. doi:10.1016/j.it.2003.12.005.
52. Hasan Z, Cliff JM, Dockrell HM, Jamil B, Irfan M, Ashraf M, et al. CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. PLoS One (2009) 4:e8459. doi:10.1371/journal.pone.0008459.
53. Feng WX, Flores-Villanueva PO, Mokrousov I, Wu XR, Xiao J, Jiao WW, et al. CCL2-2518 (A/G) polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis (2012) 16:150-6. doi:10.5588/ijtld.11.0205.
54. Quesniaux VF, Jacobs M, Allie N, Grivennikov S, Nedospasov SA, Garcia I, et al. TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun (2010) 11:157-79. doi:10.1159/000289204.
55. Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, Takatsu K, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol (2007) 179:2509-19.
56. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother (2001) 12:133-50.
57. Shattock RJ, Friedland JS, Griffin GE. Modulation of HIV transcription in and release from human monocytic cells following phagocytosis of Mycobacterium tuberculosis. Res Virol (1993) 144:7-12. doi:10.1016/S0923-2516(06)80005-1.
58. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest (1995) 95:2324-31. doi:10.1172/JCI117924.
59. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. J Infect Dis (1998) 177:1332-8.
60. Toossi Z, Nicolacakis K, Xia L, Ferrari NA, Rich EA. Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 15:325-31. doi:10.1097/00042560-199708150-00001.
61. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 157:1271-8.
62. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol (2009) 10:943-8. doi:10.1038/ni.1781.
63. Fietta AM, Morosini M, Meloni F, Bianco AM, Pozzi E. Pharmacological analysis of signal transduction pathways required for Mycobacterium tuberculosis-induced IL-8 and MCP-1 production in human peripheral monocytes. Cytokine (2002) 19:242-9. doi:10.1006/cyto.2002.1968.
64. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol (2009) 41:998-1001. doi:10.1016/j.biocel.2008.07.018.
65. Ranjbar S, Jasenosky LD, Chow N, Goldfeld AE. Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway. PLoS Pathog (2012) 8:e1002620. doi:10.1371/journal.ppat.1002620.
66. Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for toll-like receptors. Nat Rev Microbiol (2010) 8:296-307. doi:10.1038/nrmicro2321.
67. Bulut Y, Michelsen KS, Hayrapetian L, Naiki Y, Spallek R, Singh M, et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem (2005) 280:20961-7. doi:10.1074/jbc.M411379200.
68. Jung SB, Yang CS, Lee JS, Shin AR, Jung SS, Son JW, et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun (2006) 74:2686-96. doi:10.1128/IAI.74.5.2686-2696.2006.
69. Bhat KH, Chaitanya CK, Parveen N, Varman R, Ghosh S, Mukhopadhyay S. Proline-proline-glutamic acid (PPE) protein Rv1168c of Mycobacterium tuberculosis augments transcription from HIV-1 long terminal repeat promoter. J Biol Chem (2012) 287:16930-46. doi:10.1074/jbc.M111.327825.
70. Keane J, Ni Cheallaigh C. Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge. J Rheumatol (2008) 35:1238-9.
71. Salgame P. Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol (2005) 17:374-80. doi:10.1016/j.coi.2005.06.006.
72. Ranjbar S, Boshoff HI, Mulder A, Siddiqi N, Rubin EJ, Goldfeld AE. HIV-1 replication is differentially regulated by distinct clinical strains of Mycobacterium tuberculosis. PLoS One (2009) 4:e6116. doi:10.1371/journal.pone.0006116.
73. Zhang Y, Broser M, Rom WN. Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. Proc Natl Acad Sci U S A (1994) 91:2225-9. doi:10.1073/pnas.91.6.2225.
74. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis (Edinb) (2005) 85:53-64. doi:10.1016/j.tube.2004.09.011.
75. Warfel AH, Thorbecke GJ, Belsito DV. Synergism between interferon-gamma and cytokines or lipopolysaccharide in the activation of the HIV-LTR in macrophages. J Leukoc Biol (1995) 57:469-76.
76. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med (1990) 172:151-8. doi:10.1084/jem.172.1.151.
77. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA (1999) 282:677-86. doi:10.1001/jama.282.7.677.
78. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA (1992) 268:504-9. doi:10.1001/jama.1992.03490040080029.
79. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, Fountain JJ, et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A (2008) 105:10961-6. doi:10.1073/pnas.0801496105.
80. Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, Germain RN. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity (2011) 34:807-19. doi:10.1016/j.immuni.2011.03.022.
81. Gallegos AM, Pamer EG, Glickman MS. Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J Exp Med (2008) 205:2359-68. doi:10.1084/jem.20080353.
82. Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, Salinas-Carmona MC. Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses (2006) 22:45-51. doi:10.1089/aid.2006.22.45.
83. Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, Chenoweth DE, et al. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol (1989) 142:3553-9.
84. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med (1999) 340:367-73. doi:10.1056/NEJM199902043400507.
85. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, et al. HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol (2007) 179:6973-80.
86. Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, Sturgeon TJ, et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 5:e9611. doi:10.1371/journal.pone.0009611.
87. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 23:1717-25. doi:10.1097/QAD.0b013e32832d3b6d.
88. Kumawat K, Pathak SK, Spetz AL, Kundu M, Basu J. Exogenous Nef is an inhibitor of Mycobacterium tuberculosis-induced tumor necrosis factor-alpha production and macrophage apoptosis. J Biol Chem (2010) 285:12629-37. doi:10.1074/jbc.M109.073320.
89. Patel NR, Swan K, Li X, Tachado SD, Koziel H. Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. J Leukoc Biol (2009) 86:53-60. doi:10.1189/jlb.0908574.
90. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 365:1471-81. doi:10.1056/NEJMoa1013911.
91. Lawn SD, Butera ST, Shinnick TM. Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect (2002) 4:635-46. doi:10.1016/S1286-4579(02)01582-4.
92. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 8:516-23. doi:10.1016/S1473-3099(08)70184-1.
93. Oliver BG, Haddow LJ, Agarwal U, Kumar M, Easterbrook PJ, Moosa MY, et al. Pre-antiretroviral therapy plasma levels of CCL2 may aid in the prediction of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV patients after they commence antiretroviral therapy. J Acquir Immune Defic Syndr (2013) 63:e72-4. doi:10.1097/QAI.0b013e31828e6182.
94. Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med (2000) 192:347-58. doi:10.1084/jem.192.3.347.
95. Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 6:5-9. doi:10.1016/j.chom.2009.06.006.
96. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med (2007) 204:705-14. doi:10.1084/jem.20062411.
97. Shen Y, Shen L, Sehgal P, Huang D, Qiu L, Du G, et al. Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol (2004) 78:14023-32. doi:10.1128/JVI.78.24.14023-14032.2004.
98. Shen Y, Zhou D, Chalifoux L, Shen L, Simon M, Zeng X, et al. Induction of an AIDS virus-related tuberculosis-like disease in macaques: a model of simian immunodeficiency virus-Mycobacterium coinfection. Infect Immun (2002) 70:869-77. doi:10.1128/IAI.70.2.869-877.2002.